Experimental Triple-Action Drug Retatrutide Matches Bariatric Surgery Weight Loss

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Obesity is a chronic disease affecting hundreds of millions of people, often treated with surgery or daily shots.

Matches surgery results.Before this drug, bariatric surgery was the only way to lose 30 percent of total body weight. Now nearly half of patients on the highest dose achieved that same dramatic result with just a weekly injection.
Triple hormone targeting.Unlike Ozempic and Wegovy which hit only one or two hormone receptors, retatrutide targets GIP, GLP-1 and glucagon. This triple action may unlock greater weight loss for patients who did not respond well to existing medications.
70 pounds average loss.Patients lost an average of 70.3 pounds over 80 weeks, a scale of weight reduction previously only seen after invasive surgery. This offers a non-surgical path for people struggling with severe obesity.
Once weekly convenience.Before this trial, effective medical weight loss often required daily injections or pills. Retatrutide’s once-weekly dosing could make consistent treatment much easier for patients to stick with long term.

A new experimental once-weekly injection has delivered weight loss results comparable to bariatric surgery, according to clinical trial data released by the drugmaker Eli Lilly. Patients taking retatrutide lost an average of 70.3 pounds over 80 weeks, with nearly half of those on the highest dose shedding up to 30 percent of their total body weight.

The drug targets three hormone receptors: GIP, GLP-1 and glucagon, earning it the nickname of a “triple agonist.” Unlike current blockbuster medications such as Ozempic or Wegovy, which hit one or two receptors, retatrutide’s glucagon-targeting effect may help the body burn extra energy while also curbing appetite and improving blood sugar control. In the trial, 45 percent of patients taking the 12 milligram dose lost at least 30 percent of their body weight, a result Eli Lilly says is comparable to what is seen with weight loss surgery.

For context, a major trial of semaglutide, the active ingredient in Wegovy, found an average weight loss of 14.9 percent over 68 weeks. Another trial of tirzepatide, the active ingredient in Zepbound, showed up to 22.5 percent weight loss over 72 weeks. Retatrutide’s results come as prescriptions for GLP-1 drugs among U.S. adults have more than quadrupled since 2021, according to Epic Research data.

Safety and Next Steps

Retatrutide remains experimental and has not been approved by the U.S. Food and Drug Administration. The most common side effects reported were gastrointestinal, including nausea, diarrhea and vomiting. Some patients also experienced mild to moderate urinary tract infections or skin discomfort. The discontinuation rate due to side effects was highest at the 12 mg dose, reaching 11.3 percent.

The company expects to seek FDA approval in late 2027 or early 2028. The results have not yet been published in a peer-reviewed journal. Medical professionals caution that safety and effectiveness will be fully evaluated by regulators before the drug becomes available outside clinical trials. Anyone buying or selling retatrutide now is dealing with unverified, potentially dangerous substances. With more data on the horizon, researchers are optimistic that this triple-acting approach could offer a powerful new option for people living with obesity.

Bariatric Surgery Obesity Treatment Retatrutide Weight Loss

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.